@ ( @ % ) of @ patients in the rituximab group and @ ( @ % ) of @ patients in the placebo group had treatment failure within @ weeks ( Kaplan-Meier cumulative incidence @ % for rituximab vs @ % for placebo ( hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p = @ ) .